aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dy...
September 27 2017 - 8:00AM
aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged
in the discovery and development of immunology-based therapeutics,
harnessing new pathway insights from human Physiocrine proteins, to
treat patients suffering from severe, rare immune-mediated
diseases, as well as various cancers, today announced participation
in the upcoming 22nd International Annual Congress of the World
Muscle Society (WMS) being held October 3 - 7, 2017 in Saint Malo,
France.
Poster Presentation: Thursday October 5, 2017 from 15:30
– 17:00 (CEST)
- Title: Results of a Phase 1b/2 Study of
ATYR1940 in Adolescents and Young Adults With Early-onset
Facioscapulohumeral Muscular Dystrophy (FSHD) (ATYR1940-C-003)
- Author and Presenter: Gennyne Walker, Ph.D.,
aTyr Pharma, Inc., San Diego, CA
- Supporting Authors: Russel J Butterfield,
Katherine Mathews, Laurent Servais, John Day, Teresa Gidaro, Sanjay
Shukla, Lorenzo Maggi
In this exploratory, open-label study, Resolaris was generally
well tolerated at doses up to 3.0 mg/kg once weekly in patients
aged 16 to 20 years with early-onset FSHD. 63% of patients (5
of 8) had increases from baseline in their Manual Muscle Test
(MMT), a validated assessment tool that measures muscle strength,
with a mean change from baseline of +3.8%. In addition, 67% of
patients measured (4 of 6) had improvement in their Individualized
Neuromuscular Quality of Life (INQoL) score, a validated patient
reported outcome measuring a patient’s level of disease burden. On
average, patients did not have a worsening of their disease burden
as measured by INQoL. No signs of general immunosuppression were
observed, and low-level ADA signals did not result in clinical
symptoms.
aTyr believes these data are supportive of further advancement
of Resolaris.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development
of innovative medicines for patients using its knowledge of
Physiocrine biology, a newly discovered set of immunological and
physiological pathways. To date, aTyr has generated three
innovative therapeutic programs with three different biologic
modalities based on its knowledge of the Resokine pathway to treat
patients suffering from severe, rare immune-mediated diseases, as
well as various cancers. The Resolaris and iMod.Fc programs are
agonists of the Resokine pathway designed to temper immune system
engagement in diseases characterized by excessive immune cell
involvement. aTyr’s third program, ORCA, represents a novel,
proprietary pathway in immuno-oncology that utilizes antibody
approaches to block the Resokine pathway and ‘release multiple
brakes’ on the immune system in the tumor cell environment. aTyr
has built an intellectual property estate, to protect its pipeline,
comprising over 220 issued patents or allowed patent applications
that are owned or exclusively licensed, including over 300
potential Physiocrine-based protein compositions. For more
information, please visit http://www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act.
Forward-looking statements are usually identified by the use of
words such as “anticipates,” “believes,” “estimates,” “expects,”
“intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,”
and variations of such words or similar expressions. We intend
these forward-looking statements to be covered by such safe harbor
provisions for forward-looking statements and are making this
statement for purposes of complying with those safe harbor
provisions. These forward-looking statements, including statements
regarding the potential and potential therapeutic benefits of
Resolaris, the ability of the Company to successfully advance its
pipeline or product candidates, undertake certain development
activities and accomplish certain development goals, and the scope
and strength of our intellectual property portfolio, reflect our
current views about our plans, intentions, expectations, strategies
and prospects, which are based on the information currently
available to us and on assumptions we have made. Although we
believe that our plans, intentions, expectations, strategies and
prospects as reflected in or suggested by those forward-looking
statements are reasonable, we can give no assurance that the plans,
intentions, expectations or strategies will be attained or
achieved. Furthermore, actual results may differ materially from
those described in the forward-looking statements and will be
affected by a variety of risks and factors that are beyond our
control including, without limitation, risks associated with the
discovery, development and regulation of our Physiocrine-based
product candidates, as well as those set forth in our most recent
Annual Report on Form 10-K for the year ended December 31, 2016 and
in our other SEC filings. Except as required by law, we assume no
obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact:Mark JohnsonSr.
Director, Investor Relationsmjohnson@atyrpharma.com858-223-1163
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Aug 2024 to Sep 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Sep 2023 to Sep 2024